• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多药转运体作用机制的动力学分析

Kinetic analysis of the mechanism of action of the multidrug transporter.

作者信息

Ashida H, Oonishi T, Uyesaka N

机构信息

Division of Biomedical Information Sciences, National Defense Medical College Research Institute, Saitama 359-8513, Japan.

出版信息

J Theor Biol. 1998 Nov 21;195(2):219-32. doi: 10.1006/jtbi.1998.0787.

DOI:10.1006/jtbi.1998.0787
PMID:9822564
Abstract

To clarify the mechanistic role of PGP (P-glycoprotein) in multidrug transport, we constructed a kinetic model composed of four compartments: (1) the extracellular space; (2) the space in the membrane; (3) the intracellular space; and (4) the pore-like space in the PGP molecule. The kinetics of the concentration of ADM (adriamycin) in each compartment were formulated based on the assumptions that (a) the movement of ADM between two compartments by diffusion is dependent on a dynamic distribution coefficient introduced here, (b) the uptake of ADM into the pore-like structure by the pump mechanism activated by ATP is described by enzyme kinetics, (c) the movement of ADM out of the pore-like structure to the extracellular medium through a valve-like mechanism is also expressed by enzyme kinetics. The mathematical analysis of the exact solution can explain the distinct effects of verapamil and vanadate on the accumulation and release of ADM, where verapamil inhibits the efflux by the valve-like mechanism and vanadate blocks the influx by the pump mechanism. We also performed a numerical calculation with this model for a quantitative explanation and found the valid parameter values to fit the experimental data. These results support the modified hydrophobic vacuum cleaner model.

摘要

为阐明P-糖蛋白(PGP)在多药转运中的机制作用,我们构建了一个由四个隔室组成的动力学模型:(1)细胞外空间;(2)膜内空间;(3)细胞内空间;以及(4)PGP分子中的孔状空间。基于以下假设制定了每个隔室中阿霉素(ADM)浓度的动力学:(a)ADM在两个隔室之间通过扩散的移动取决于此处引入的动态分配系数,(b)通过ATP激活的泵机制将ADM摄取到孔状结构中由酶动力学描述,(c)ADM通过类似阀门的机制从孔状结构移动到细胞外介质也由酶动力学表示。精确解的数学分析可以解释维拉帕米和钒酸盐对ADM积累和释放的不同影响,其中维拉帕米通过类似阀门的机制抑制流出,而钒酸盐通过泵机制阻断流入。我们还用这个模型进行了数值计算以进行定量解释,并找到了符合实验数据的有效参数值。这些结果支持了改进的疏水真空吸尘器模型。

相似文献

1
Kinetic analysis of the mechanism of action of the multidrug transporter.多药转运体作用机制的动力学分析
J Theor Biol. 1998 Nov 21;195(2):219-32. doi: 10.1006/jtbi.1998.0787.
2
Kinetic analysis of P-glycoprotein-mediated doxorubicin efflux.
J Pharmacol Exp Ther. 1992 Nov;263(2):762-6.
3
Transport of doxorubicin in mast cell granules and the effect of the calcium antagonist verapamil.阿霉素在肥大细胞颗粒中的转运及钙拮抗剂维拉帕米的作用。
Anticancer Res. 1999 Mar-Apr;19(2A):1101-8.
4
Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.通过加速药物被动跨质膜渗透来调节P-糖蛋白介导的多药耐药性。
FEBS J. 2007 Dec;274(23):6204-14. doi: 10.1111/j.1742-4658.2007.06140.x. Epub 2007 Nov 6.
5
Is P-glycoprotein (ABCB1) a phase 0 or a phase 3 colchicine transporter depending on colchicine exposure conditions?根据秋水仙碱的暴露条件,P-糖蛋白(ABCB1)是0相还是3相秋水仙碱转运体?
Toxicol Appl Pharmacol. 2006 Dec 1;217(2):153-60. doi: 10.1016/j.taap.2006.08.004. Epub 2006 Aug 10.
6
Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.与人P-糖蛋白结合特性的表征:[3H]维拉帕米放射性配体结合测定法的开发。
J Pharmacol Exp Ther. 1999 Jan;288(1):348-57.
7
Pumping of drugs by P-glycoprotein: a two-step process?P-糖蛋白对药物的转运:一个两步过程?
J Pharmacol Exp Ther. 2003 Dec;307(3):846-53. doi: 10.1124/jpet.103.056960. Epub 2003 Oct 8.
8
P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.P-糖蛋白不会降低活细胞中质膜细胞外小叶的底物浓度。
Cancer Res. 2001 Nov 1;61(21):7763-9.
9
The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter.膜脂质环境调节药物与P-糖蛋白多药转运体的相互作用。
Biochemistry. 1999 May 25;38(21):6887-96. doi: 10.1021/bi990064q.
10
ATP occlusion by P-glycoprotein as a surrogate measure for drug coupling.P-糖蛋白介导的ATP阻断作为药物偶联的替代指标。
Biochemistry. 2008 Mar 11;47(10):3294-307. doi: 10.1021/bi7021393. Epub 2008 Feb 15.

引用本文的文献

1
Application of Hybrid Functional Groups to Predict ATP Binding Proteins.混合官能团在预测ATP结合蛋白中的应用。
ISRN Comput Biol. 2014 Jan 8;2014:581245. doi: 10.1155/2014/581245.
2
Alkyl-capped silicon nanocrystals lack cytotoxicity and have enhanced intracellular accumulation in malignant cells via cholesterol-dependent endocytosis.烷基封端的硅纳米晶体无细胞毒性,并且通过胆固醇依赖性内吞作用在恶性细胞中具有增强的细胞内积累。
Small. 2009 Feb;5(2):221-8. doi: 10.1002/smll.200800903.
3
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.
血脑屏障处活性药物外排的药代动力学后果。
Pharm Res. 2006 Apr;23(4):705-17. doi: 10.1007/s11095-006-9780-0. Epub 2006 Apr 7.
4
The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.MDCKII-hMDR1细胞汇合单层的P-糖蛋白转运的基本质量作用速率常数。
Biophys J. 2005 Jan;88(1):715-38. doi: 10.1529/biophysj.104.045633. Epub 2004 Oct 22.